Back

Safety and clinical effects of sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy

21 May 2023 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: Heart failure with preserved ejection fraction (HFpEF) 1 Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ani Nalbandian

Columbia University Irving Medical Centre, New York (United States of America)

7 More presentations in this session

Presentation thumbnail
Impact of temporary LV systolic dysfunction on long-term clinical outcome in patients with preserved ejection fraction after acute myocardial infarction
Doctor J. Kim (Seoul, KR)
Abstract Slides
Presentation thumbnail
Vascular stiffness, cardiac chamber stiffness and cardiovascular risk factors in women versus men with pre-HFpEF; a report from the PARABLE trial.
Doctor B. Wong (Dublin, IE)
Abstract Slides
Presentation thumbnail
Left-to-right ventricular volume ratio and outcome in heart failure with preserved ejection fraction
Doctor A. Aimo (Pisa, IT)
Abstract Slides
Presentation thumbnail
Coronary microvascular dysfunction, central and overall obesity and metabolic and fibrotic biomarkers in patients with heart failure with preserved ejection fraction (data from PROMIS-HFpEF)
Mr M. Erhardsson (Stockholm, SE)
Abstract Slides
Presentation thumbnail
The prognostic value of hypoxemic burden measured by overnight oximetry in heart failure patients with preserved ejection fraction
Miss S. Mourmans (Maastricht, NL)
Abstract Slides

Access the full session

Session thumbnail
Heart failure with preserved ejection fraction (HFpEF) 1

The Event

Event poster

Heart Failure 2023

21 May 2023 09:00 CET
You may be interested in
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction
thumbnail
Webinar
Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction
thumbnail
Webinar
Acute heart failure in patients with preserved ejection fraction (AHFPEF)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources